Would you please start by giving a brief overview of BCG-unresponsive NMIBC? Nonmuscle Invasive Bladder Cancer Prior to recent therapeutic innovations in the bladder space what challenges or unmet ...
Please review the standard treatment options (intravesical chemotherapy, PD-L1 inhibitors, other immunotherapeutic options) currently available for patients with BCG-unresponsive NMIBC.
“Our findings highlight the coordinated interplay between GCN2 and p53 regulation during nutrient stress and provide insight into how they could be targeted in developing new therapeutic strategies ...
"The interplay between the microbiome and bladder cancer is very complex," says Ilaha Isali, MD, MSc. Isali: The interplay between the microbiome and bladder cancer is very complex. There is still ...
Bayer seeks approval in China for darolutamide plus ADT for mHSPC, marking a potential third indication. The ARANOTE trial showed darolutamide plus ADT significantly improved rPFS and OS compared to ...
"This idea that physicians and medical teams always feel that they need to be available at all hours of the day really starts to stress people." says Chad W. M. Ritenour, MD, FACS. In this video, Chad ...
According to iota Biosciences, the device is “designed to deliver electrical stimulation directly to the bladder wall, inducing contractions that facilitate bladder emptying in individuals impacted by ...
“It's a good problem to have, because we're thinking about a previous era in which we didn't have many options besides more BCG vs cystectomy,” says Vikram M. Narayan, MD. In this video, Vikram M.
CMS issued a J-code for Anktiva, effective January 1, 2025, aiding billing and reimbursement processes for intravesical therapies. Anktiva, approved by the FDA in April 2024, is used with BCG for ...
Spina bifida patients frequently have bacteria in their urinary microbiomes, challenging the notion of sterile urine and complicating UTI diagnosis. E. coli is a dominant organism in the microbiomes ...